An FDA advisory panel agreed Wednesday that GlaxoSmithKline's Rotarix vaccine was safe and effective, recommending the anti-rotavirus shot for agency approval. Rotarix is designed to help protect infants from gastrointestinal illness caused by that virus. The FDA is set to say yea or nay by April 3. If approved for sale, Rotarix will compete with Merck's RotaTeq, which has been on the market since 2006. Report